Navigation Links
Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

PRINCETON, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, January 13, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

    Contact: Laura S. Choi                   Nichol Ochsner

'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medarex to Present at the RBC Capital Markets Healthcare Conference
2. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
3. Medarex Announces 2008 Third Quarter Financial Results
4. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
8. Medarex Announces July 10 Live Webcast of R&D Day Event
9. Medarex to Present at the Jefferies Second Annual Healthcare Conference
10. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
11. Medarex to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Empowering biomedical researchers with ... Cubresa Inc. today announced its MR Compatible Small ... PET Scanner uses silicon photomultiplier detector technology, so ... machines from manufacturers like Bruker and Agilent,” said ... Canada. “This enables simultaneous PET and MRI data ...
(Date:5/27/2015)... , May 27, 2015  US-Australian drug discovery and ... announced today that it will present at the Brain Tumor ... on May 29, 2015. The venue is the ... Manhattan . The Brain Tumor Biotech ... the pharmaceutical industry and the investment community to promote innovative ...
(Date:5/26/2015)... Miami (PRWEB) May 26, 2015 ... a new stem cells clinic in Buenos Aires, Argentina. ... a renowned critical care specialist. Pastrana has assembled a ... endocrinology and orthopedics in her state-of-the-art Puerto Madero office. ... operate phase I to phase IV clinical studies in ...
(Date:5/26/2015)... 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... CEO, will provide an update on the progress of Sangamo,s ... the company,s business strategy at 1:30pm ET on Monday, June ... conference is being held in New York, NY ... and may be accessed via a link on the Sangamo ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2Novogen to Present at Brain Tumor Biotech Summit 2015 2Novogen to Present at Brain Tumor Biotech Summit 2015 3Novogen to Present at Brain Tumor Biotech Summit 2015 4Novogen to Present at Brain Tumor Biotech Summit 2015 5Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... Tengion, Inc. (Nasdaq: TNGN ), a leader ... definitive agreements with certain investors in connection with a PIPE ... of 1933, as amended.  Medtronic (NYSE: MDT ), ... and, as part of its investment, secured a right of ...
... Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN ... eduction f or A dults R eceiving ... Overlake Hospital Medical Center in Bellevue and other major hospital ... determine a personalized warfarin dose for individual patients to reduce ...
... 28, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... for the third quarter and first nine months of fiscal ... Quarter of Fiscal 2011 ...
Cached Biology Technology:Tengion Announces Pricing of $31.4 Million Private Placement 2Tengion Announces Pricing of $31.4 Million Private Placement 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3WARFARIN Study Launched at Overlake Hospital Medical Center to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 2China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 3China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 4China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 5China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 6China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 7China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 8China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 9China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 10China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results 11
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... December 17th, 2013 - Eurofins Medigenomix, a part of ... Orion Diagnostica Oy, an in vitro diagnostics company specialising ... systems, announced that they have signed a co-exclusive technology ... for the SIBA isothermal nucleic acid detection technology in ...
... birth to live young, rather than laid eggs, and over ... reproductive mode, according to research published in print in ... unusual and controversial finding, and a major overturn of an ... Assistant Professor of Biology in the Columbian College of Arts ...
... controlling the temperature of silica rods as they grow, ... Laboratory could be setting the stage for advances in ... and more. The goal of fabricating fixed-size one-dimensional ... diameter during growth has long eluded scientists. Now, Panos ...
Cached Biology News:Ancestor of snakes, lizards likely gave birth to live young 2ORNL devises recipe to fine-tune diameter of silica rods 2
... This thin foil heat sealing material ... pressure from a screw down heated ... is a useful method for sample ... over the existing seal. Ideal for ...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
... Western Blot Strong Antibody Stripping Solution is ... blots that have been developed with chemiluminescence ... is not recommended for stripping colorimetric substrates ... not possible to effectively remove substrates that ...
...
Biology Products: